Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 467-476

  Ulloa, Carol M ^a   Towfigh, Allen ^a   Safdieh, Joseph ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiepileptic drugs; Levetiracetam; Partial onset seizures

Indexed keywords

CALCIUM CHANNEL N TYPE; CARBAMAZEPINE; CELL PROTEIN; CLOBAZAM; CYTOCHROME P450; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETIRACETAM; GABAPENTIN; KEPPRA XR; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; SYNAPTIC VESICLE PROTEIN 2A; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; WARFARIN;

ADD ON THERAPY; ADJUVANT THERAPY; AGGRESSION; AGITATION; ANTICONVULSANT ACTIVITY; ANTISOCIAL BEHAVIOR; ANXIETY; APATHY; AREA UNDER THE CURVE; ASTHENIA; BEHAVIOR DISORDER; CALORIC INTAKE; CLINICAL TRIAL; COMMON COLD; DEPERSONALIZATION; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FLU LIKE SYNDROME; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; HOSTILITY; HUMAN; INFECTION; INFLUENZA; IRRITABILITY; LACTATION; LIPID DIET; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MENTAL INSTABILITY; MONOTHERAPY; MOOD DISORDER; MOUTH ULCER; MYOCLONUS SEIZURE; NAUSEA; NERVOUSNESS; NEUROSIS; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSONALITY DISORDER; PHYSICAL CHEMISTRY; PREGNANCY; RHINITIS; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOMNOLENCE; TONIC CLONIC SEIZURE; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

EID: 70449727382     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Note

References (69)

1. Peltola J, Coetzee C, Jiménez F, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia. 2009;50(3):406-414.
2. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia. 2000;41(10):1276-1283. (Pubitemid 30766152)
3. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236-242. (Pubitemid 30604624)
4. Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia. 2000;41(9):1179-1186. (Pubitemid 30692334)
5. Rouits E, Burton I, Guénolé E, Troenaru MM, Stockis A, Sargentini-Maier ML. Pharmacokinetics of levetiracetam XR 500 mg tablets. Epilepsy Res. 2009;84(2-3):224-231.
6. Noyer M, Gillard M, Matagne A, Hénichart JP, Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286(2):137-146.
7. Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353(2-3):191-206. (Pubitemid 28352266)
8. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol. 1969;25(3):295-330.
9. Vinogradova LV, van Rijn CM. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia. 2008;49(7):1160-1168.
10. Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 1998;284(2):474-479. (Pubitemid 28086631)
11. Ji-qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Epilepsia. 2005;46(9):1362-1370. (Pubitemid 43919474)
12. Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure. 2001;10(4):279-286. (Pubitemid 32705452)
13. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43(1):9-18. (Pubitemid 34215447)
14. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001;306(1-2):5-8. (Pubitemid 32524284)
15. Angehagen M, Margineanu DG, Ben-Menachem E, Rönnbäck L, Hansson E, Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport. 2003;14(3):471-475. (Pubitemid 36337953)
16. Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett. 2008;436(3):289-293.
17. Desaulles E, Boux O, Feltz P. Caffeine-induced Ca2+ release inhibits GABAA responsiveness in rat identified native primary afferents. Eur J Pharmacol. 1991;203(1):137-140.
18. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000;42(4):281-285. (Pubitemid 30743409)
19. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861-9866. (Pubitemid 38869327)
20. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006;536(1-2):102-108.
21. Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A. 1999;96(26):15268-15273.
22. Keppra XR [Package insert]. Smyrna, GA: UCB Pharma, Inc, 2008.
23. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707-724.
24. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77-85.
25. Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther. 2005;77(6):529-541. (Pubitemid 40824966)
26. Glauser TA, Mitchell WG, Weinstock A, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007;48(6):1117-1122. (Pubitemid 46854880)
27. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001;42(12):1574-1579.
28. Browne TR, Szabo GK, Leppik IE, Josephs E, Paz J, Baltes E, Jensen CM. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol. 2000;40(6):590-595.
29. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47(1-2):55-63. (Pubitemid 32973648)
30. Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46(2):93-99. (Pubitemid 32709922)
31. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia. 2002;43(7):697:702. (Pubitemid 34774250)
32. Gidal BE, Baltès E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 2005;64(1-2):1-11. (Pubitemid 40726160)
33. Perucca E, Gidal BE, Baltès E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 2003;53(1-2):47-56. (Pubitemid 36170170)
34. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66(11):1654-1660. (Pubitemid 43964617)
35. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43(5):518-524.
36. Grosso S, Franzoni E, Coppola G, et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure. 2005;14(4):248-253. (Pubitemid 40704329)
37. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure. 2005;14(1):66-71. (Pubitemid 40103960)
38. Callenbach PM, Arts WF, ten Houten R, et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Eur J Paediatr Neurol. 2008;12(4):321-327.
39. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70(8):607-616. (Pubitemid 351294638)
40. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U; Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007;69(18):1751-1760.
41. Safdieh J, Harden C. Levetiracetam: past, present and future. Future Medicine. 2006;1(4):365-371.
42. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402-408.
43. Alsaadi TM, Shatzel A, Marquez AV, Jorgensen J, Farias S. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure. 2005;14(2):139-142. (Pubitemid 40214742)
44. Alsaadi TM, Koopmans S, Apperson M, Farias S. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure. 2004;13(1):58-60. (Pubitemid 38139667)
45. Alsaadi TM, Thieman C. Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure. 2003;12(3):154-156. (Pubitemid 36452286)
46. Alsaadi TM, Thieman C, Zusman EE. Levetiracetam monotherapy for adults with localization-related epilepsy. Epilepsy Behav. 2002;3(5):471-474. (Pubitemid 35460417)
47. Abou-Khalil B. Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf. 2005;28(10):871-890. (Pubitemid 41428544)
48. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001;47(1-2):77-90. (Pubitemid 32973650)
49. Bootsma HP, Ricker L, Diepman L, et al. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2007;10(2):296-303. (Pubitemid 46432220)
50. Depondt C, Yuen AW, Bell GS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry. 2006;77(1):101-103. (Pubitemid 43022705)
51. Abou-Khalil B, Schaich L. Long-term efficacy of levetiracetam for partial seizures. Seizure. 2005;14(8):577-585. (Pubitemid 41782480)
52. Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology. 2004;63(3):568-570. (Pubitemid 39031397)
53. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61(5):704-706. (Pubitemid 37082613)
54. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. 2003;4(2):124-132. (Pubitemid 37184583)
55. Brodtkorb E, Klees TM, Nakken KO, Lossius R, Johannessen SI. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav. 2004;5(2):231-235. (Pubitemid 38461213)
56. Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 2003;4(6):702-709. (Pubitemid 38035693)
57. Cramer JA, Leppik IE, Rue KD, Edrich P, Krämer G. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res. 2003;56(2-3):135-145. (Pubitemid 37474114)
58. Isoherranen N, Spiegelstein O, Bialer M, et al. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia. 2003;44(10):1280-1288. (Pubitemid 37280372)
59. Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2006;67(10):1876-1879. (Pubitemid 44900776)
60. Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48(6):1111-1116. (Pubitemid 46854871)
61. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy. Ann Neurol. 1991;29(4):356-363.
62. Sills GJ. Seizures beget seizures: a lack of experimental evidence and clinical relevance fails to dampen enthusiasm. Epilepsy Curr. 2007;7(4):103-104.
63. Dudek FE, Bertram EH, Staley KJ. Antiepileptogenesis therapy with levetiracetam: data from kindling versus status epilepticus models. Epilepsy Curr. 2008;8(1):28-30.
64. Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol. 2009 Jan 24. Epub ahead of print.
65. Wagner GL, Wilms EB, Van Donselaar CA, Vecht ChJ. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure. 2003;12(8):585-586.
66. Gidal BE, Sheth RD, Magnus L, Herbeuval AF. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res. 2003;56(2-3):121-126. (Pubitemid 37464925)
67. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296- 1310. (Pubitemid 32804122)
68. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther. 1988;44(5):540-545. (Pubitemid 19002867)
69. Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs. 2007;21(9):765-774.